UBS O'Connor’s ArriVent BioPharma AVBP Stock Holding History

UBS O'Connor’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,181	Closed	-$468K	–	646
2024 Q1	$468K	Buy	+26,181	New	+$528K	0.01%	338

Other funds holding AVBP

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's AVBP Position: Q2 2024 in Review

UBS O'Connor sold out of ArriVent BioPharma (AVBP) in Q2 2024, closing a stake of 26,181 shares — an estimated $468K sold.

UBS O'Connor first reported a position in AVBP in Q1 2024 and held it in 1 quarter. The position peaked at $468K in Q1 2024. 54 funds tracked by Wall St. Rank hold AVBP as of Q2 2024.

UBS O'Connor reported no remaining ArriVent BioPharma position as of Q2 2024 after selling out during the quarter.
UBS O'Connor sold 26,181 ArriVent BioPharma shares in Q2 2024, an estimated $468K.
UBS O'Connor first reported a position in ArriVent BioPharma in Q1 2024 and held it in 1 quarter.
UBS O'Connor's ArriVent BioPharma position peaked at $468K in Q1 2024.
54 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.